Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.72 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 2/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378576 | 1.00 | PLCG1 (0.72) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL15846216 | 0.85 | PLCG1 (0.64) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL4250234 | 0.84 | PLCG1 (1.00) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL28680071 | 0.83 | PSIP1 (0.59) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL28023659 | 0.82 | PLCG1 (0.60) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL31255958 | 0.80 | PLCG1 (0.69) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL9704080 | 0.80 | PLCG1 (0.69) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL5083652 | 0.80 | PLCG1 (0.69) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL5340247 | 0.79 | PLCG1 (0.62) | PLCG1CA1CA2CA4CA6 | |
| SCHEMBL27638996 | 0.79 | PLCG1 (0.62) | PLCG1CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038395-A1 | BENZOPYRIDINONES AND BENZOPYRIMIDINONES AS PI3K INHIBITORS | ONKURE, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-109476616-B | Piperazinyl methanone NAAA inhibitors | 加利福尼亚大学董事会 | 2023-10-13 | — | — | CN | disclosed |
| EP-3774775-B1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-10-11 | — | — | EP | disclosed |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2022-11-22 | — | — | US | disclosed |
| EP-3774775-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024503-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-01-28 | — | — | US | disclosed |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2019198024-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2019-10-17 | — | — | WO | disclosed |
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2019-06-13 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| WO-2014121055-A2 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | WO | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2493303-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | Merck Sharp & Dohme Corp. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20120214847-A1 | 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011053574-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053574-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177313-A1 | PIPERZINYL METHANONE NAAA INHIBITORS | NAAA, NAA15, NAA50 | PLCG1 942/4885CA1 1762/4885CA2 2876/4885 |
| US-20210024503-A1 | 4-OXO-3,4-DIHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, CCNI, IRF3 | PLCG1 3412/4885CA1 4822/4885CA2 4566/4885 |
| US-20120214847-A1 | 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | PLCG1 2692/4885CA1 3560/4885CA2 2936/4885 |
| US-10556892-B2 | Piperazinyl methanone NAAA inhibitors | NAAA, NAA50, NAA15 | PLCG1 1734/4885CA1 1783/4885CA2 2959/4885 |
| US-11505543-B2 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | EIF2AK2, CCNI, IRF3 | PLCG1 3412/4885CA1 4822/4885CA2 4566/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | PLCG1 795/4885CA1 3615/4885CA2 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.